101860-83-7

Basic information

• Product Name: 3-nitro-4-bromopropiophenone
• Synonyms: 3-nitro-4-bromopropiophenone;1-(4-bromo-3-nitrophenyl)propan-1-one;1-Propanone, 1-(4-broMo-3-nitrophenyl)-
• CAS NO: 101860-83-7
• Molecular Formula: C₉H₈BrNO₃
• Molecular Weight: 258.07
• Mol File: 101860-83-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 291.2°Cat760mmHg
• Flash Point: 129.9°C
• Appearance: /
• Density: 1.559g/cm³
• Vapor Pressure: 0.00197mmHg at 25°C
• Refractive Index: 1.58
• CAS DataBase Reference: 3-nitro-4-bromopropiophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-nitro-4-bromopropiophenone(101860-83-7)
• EPA Substance Registry System: 3-nitro-4-bromopropiophenone(101860-83-7)

Safety Data

• Hazardous Substances Data: 101860-83-7(Hazardous Substances Data)

Usage

General Description

3-nitro-4-bromopropiophenone is a chemical compound that belongs to the class of aromatic ketones. It is composed of a propiophenone backbone with a nitro group attached at the 3rd position and a bromine group at the 4th position. 3-nitro-4-bromopropiophenone is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also known for its potential as a building block in organic chemistry for the creation of more complex molecules. Due to its chemical structure, it possesses unique properties that make it useful in different chemical reactions and processes. However, it is important to handle and use this compound with caution, as it can pose health hazards and should be handled in a controlled environment.

InChI:InChI=1/C9H8BrNO3/c1-2-9(12)6-3-4-7(10)8(5-6)11(13)14/h3-5H,2H2,1H3

Upstream product

• 10342-83-3 4'-Bromopropiophenone 

Downstream Products

• 99848-81-4 6-Brom-3-propionyl-anilin 
• 98949-94-1 6-Brom-3-propyl-anilin 
• 889856-61-5 2-nitro-4-propionylbenzonitrile 

Relevant articles and documents

Syntheses and In Vitro Anticancer Properties of Novel Radiosensitizers

Series of 4-(ethylsulfonyl)-1-halogen-2-nitrobenzene (3a-e) and 1-(4-halogen-3-nitrophenyl) propan-1-one (5a-d) analogs designed as novel radiosensitizers using bromonitropropiophenone and bromonitrobenzonitrile as lead compounds were synthesized. The anticancer activities of the compounds were evaluated in vitro using human prostate cancer (DU-145) and breast cancer (MCF-7) cell lines and the MTT assay. From the series, six compounds (3b-e, 5b-c) exhibited potent growth inhibitory effects against both cell lines. The most active, compound 3d, is an iodosulfone and is significantly more potent than the lead compound 5c at 10μm. Compounds were then compared with doxorubicin, a clinically used anticancer compound for breast and prostate cancers. Our most active compound 3d is more effective than doxorubicin at the dose level of 10μm at 3days after radiation, cell viabilities of 18%, 13% compared to 87%, 94% against MCF-7, and 15%, 20% compared to 60%, 75% against DU-145 without and with radiation, respectively. At 10μm, compound 5c had no effects as compared to control, whereas compound 3d reduced DU-145 cell viability to 16% and that of MCF-7 cells to 9% even at 5days after radiation. These results are very encouraging. Future studies include testing the compounds in vivo with and without radiation. Our most active compound 3d is significantly more effective than doxorubicin or lead compound 5c at the dose level of 10μm, without and with radiation; and in MCF-7 and DU-145 cell lines. These results are very encouraging. Future studies include testing the compounds in vivo without and with radiation.

7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF

A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.